The level of circulating endothelial progenitor cells is increased in human lung cancer patients and correlates with the progression of the disease

Hohenberger, Peter; Nowak, Kai; Rafat, Neysan; Belle, Sebastian; Hanusch, C; Manegold, Christian; Weiss, C; Beck, Grietje

doi:10.1200/jco.2008.26.15_suppl.22055

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to lung cancer, both clinical analyses and laboratory studies have shown that CD133 plays a critical role in tumorigenesis in SCLC and NSCLC (10,11). However, this theory is still controversial because CD133 is not a reliable tumor stem cell marker in lung cancer according to some studies, especially in NSCLC (12,13).…”

Section: Introductionmentioning

confidence: 99%

CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer

Cui

Wang²,

Chen³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Lung cancer is the most common cause of cancerrelated death worldwide. Current investigations in the field of cancer research have intensively focused on the 'cancer stem cell' or 'tumor-initiating cell'. While CD133 was initially considered as a stem cell marker only in the hematopoietic system and the nervous system, the membrane antigen also identifies tumorigenic cells in certain solid tumors. In this study, we investigated the human lung cancer cell lines A549, H157, H226, Calu-1, H292 and H446. The results of real-time PCR analysis after chemotherapy drug selection and the fluorescence-activated cell sorting analysis showed that CD133 only functioned as a marker in the small cell lung cancer line H446. The sorted CD133+ subset presented stem cell-like features, including self-renewal, differentiation, proliferation and tumorigenic capacity in subsequent assays. Furthermore, a proportion of the CD133 + cells had a tendency to remain stable, which may explain the controversies arising from previous studies. Therefore, the CD133 + subset should provide an enriched source of tumor-initiating cells among H446 cells. Moreover, the antigen could be used as an investigative marker of the tumorigenic process and an effective treatment for small cell lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%